Vir surges 50% after COVID-19 antibody drug shown to reduce risk of death
March 11, 2021 at 06:39 AM EST
Shares of Vir Biotechnology surged 35% in premarket trading on Thursday, after the company said its experimental COVID-19 treatment, being developed with GlaxoSmithKline, significantly reduced hospitalization and death in high-risk adults.
